Join The Discussion

 

Fort Worth's new thoroughfare plan aims for more variety in street design

Fort Worth is launching a review of its master thoroughfare plan aimed at accommodating continued suburban growth and central city redevelopment with a greater variety of streets and more efficient traffic flow.

read more >

UPDATE: Could American Airlines move its headquarters?

A key linchpin in the Fort Worth economy, American Airlines Group Inc., is considering sites for a new headquarters, possibly outside the city, the airline’s CEO said this morning.

read more >

Crestwood area hoping to block planned office building

Residents of West Fort Worth’s Crestwood Association are trying to block the rezoning of a small apartment complex at White Settlement Road and North Bailey Avenue to make way for a planned office building, saying it would represent the start of commercial encroachment into their neighborhood.

read more >

Tiger Woods takes a swing at Fort Worth's Dan Jenkins - in print anyway

Rarely does Golf Digest make the news. Leave it to Dan Jenkins to change that.

read more >

Hilton Fort Worth named to Historic Hotels

The Hilton Fort Worth is one of 24 hotels named a member of the Historic Hotels of America, the Washington, D.C.-based group announced on Nov. 18.

read more >

Nicox, with Fort Worth operations, to acquire Aciex Therapeutics of Boston

Nicox S.A., an international ophthalmic company whose United States operations are based in Fort Worth, will acquire Aciex Therapeutics Inc., a private ophthalmic development pharmaceutical company in Boston, on a cash-free, debt-free basis through a reverse triangular merger.
Under terms of the proposed acquisition, Aciex shareholders will receive an upfront payment of $65 million in the form of 20,627,024 newly issued Nicox shares, plus contingent value rights giving right to shares for a potential additional value of up to $55 million.


The transaction will broaden and strengthen Nicox’s therapeutic development pipeline, which would include two phase 3 candidates, one being developed by Nicox’s partner Bausch + Lomb.
Aciex brings a near-term pipeline of ophthalmic therapeutic product candidates, including one for allergic conjunctivitis.
Aciex was founded in 2007 with technology licensed from Afferent Therapeutics LLC, a spin-out from Ora Inc.


The completion of the acquisition is subject to the approval of Nicox’s shareholders and other customary conditions.
Nicox was founded in 1996 and is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets, and an expanding international presence through partners. The company had a market cap of $271 million as of Feb. 28, 2014, and cash position of $86.1 million as of Sept. 30, 2013. Nicox employs about 134 people worldwide.
Nicox S.A. is listed on Euronext Paris.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Midterms
What was the message of the midterm elections?